Triheptanoin

Pre-clinicalActive

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Long Chain Fatty Acid Oxidation Disorders

Conditions

Long Chain Fatty Acid Oxidation Disorders

Trial Timeline

— → —

NCT ID

NCT03773770

About Triheptanoin

Triheptanoin is a pre-clinical stage product being developed by Ultragenyx Pharmaceutical for Long Chain Fatty Acid Oxidation Disorders. The current trial status is active. This product is registered under clinical trial identifier NCT03773770. Target conditions include Long Chain Fatty Acid Oxidation Disorders.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01461304	Pre-clinical	Completed	—	—	Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency
NCT02968953	Pre-clinical	Completed	—	—	Glucose Transporter 1 Deficiency Syndrome
NCT03773770	Pre-clinical	Active	—	—	Long Chain Fatty Acid Oxidation Disorders
NCT07097311	Phase 2	Recruiting	Jul 1, 2026	Apr 1, 2028	Medium-chain Acyl-CoA Dehydrogenase Deficiency
NCT06067802	Phase 2	Active	Feb 1, 2026	Jul 1, 2028	Medium-chain Acyl-CoA Dehydrogenase Deficiency
NCT06340685	Phase 1	Recruiting	Jul 11, 2024	Jun 30, 2029	Pyruvate Dehydrogenase Complex Deficiency
NCT05933200	Phase 3	Active	Feb 28, 2023	Aug 1, 2027	Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
NCT03665636	Phase 1	Completed	Oct 16, 2020	Oct 21, 2021	Glycogen Storage Disease Type I
NCT03506425	Phase 1/2	Completed	Jun 21, 2018	Mar 28, 2019	ALS
NCT02696044	Phase 2	UNKNOWN	Jun 1, 2016	Feb 1, 2022	Rett Syndrome
NCT02432768	Phase 2	Completed	Apr 1, 2015	Feb 1, 2019	Glycogen Storage Disease Type V
NCT02000960	Phase 2	UNKNOWN	Apr 1, 2014	Oct 1, 2016	Glucose Transporter Type 1 Deficiency Syndrome
NCT02036853	Phase 2	Completed	Feb 20, 2014	Jun 30, 2019	Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
NCT00947960	Phase 2	Completed	Jun 1, 2009	Jul 1, 2015	Adult Polyglucosan Body Disease

Competing Products

16 competing products in Long Chain Fatty Acid Oxidation Disorders

See all competitors

Product	Company	Stage	Hype Score
Ensitrelvir	Shionogi	Phase 2	52
TBM100	Novartis	Approved	85
GS-6615 + Placebo to match GS-6615 + Placebo to match dofetilide + Dofetilide	Gilead Sciences	Phase 1	32
Eleclazine	Gilead Sciences	Phase 1	32
Eleclazine	Gilead Sciences	Phase 1	32
Placebo + Ranolazine	Gilead Sciences	Phase 2	51
GS-6615	Gilead Sciences	Phase 1	32
Eleclazine + Eleclazine placebo	Gilead Sciences	Phase 3	76
Nirmatrelvir + Ritonavir + Placebo	Pfizer	Phase 2	51
Staccato alprazolam	UCB	Phase 3	74
Staccato alprazolam	UCB	Phase 3	74
N-803 (IL-15 Superagonist)	ImmunityBio	Phase 2	49
Anktiva	ImmunityBio	Phase 2	49
UX007	Ultragenyx Pharmaceutical	Phase 2	47
triheptanoin	Ultragenyx Pharmaceutical	Pre-clinical	18
Triheptanoin	Ultragenyx Pharmaceutical	Phase 3	72

Other Products from Ultragenyx Pharmaceutical

Crysvita (burosumab-twza) TreatmentApproved

GTX-102Phase 3

EvinacumabPhase 3

Adjuvant Immunomodulatory (IM) TherapyPhase 3

Oral prednisolone + Placebo for oral prednisolonePhase 3